GXO Logistics Inc vs Oruka Therapeutics Inc. Common Stock — how do they compare? GXO Logistics Inc trades at $45.88 (market cap $5.26B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.08B). The key difference: GXO Logistics Inc and Oruka Therapeutics Inc. Common Stock are close in size by market cap, and Oruka Therapeutics Inc. Common Stock is trading nearer its 52-week high, GXO Logistics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GXO Logistics Inc for 29 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| GXO | ORKA | |
|---|---|---|
Market Cap | $5.26B | $5.08B |
Volume | 1,088,297 | 685,276 |
Sector | Industrials | Health |
52-Week High | $65.59 | $113.08 |
52-Week Low | $44.17 | $26.19 |
Typical Hold Time | 29 Days | 0 Days |
Enterprise Value | $10.61B | $4.21B |
Signals from Pluang's Aura AI — not financial advice
GXO Logistics trades at $46.50, down 0.21% with neutral technical signals. The company shows strong revenue growth with 2026 revenue reaching $13.6B and net profit margin improving to 0.96%. Recent earnings beats and strategic partnerships in Europe and aerospace sectors demonstrate operational momentum. Analyst consensus remains strongly bullish with 16 buy ratings and a $66.67 price target, representing 43% upside potential from current levels.
The stock presents compelling value with attractive valuation metrics including P/S of 0.39x, though elevated P/E of 41.15x reflects growth expectations. Key risks include margin pressure from new business at lower incremental margins and competitive industry dynamics. The improving freight industry outlook and GXO's market leadership position support long-term growth prospects despite near-term execution challenges.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →